Anaplastic lymphoma kinase as a new therapeutic target in inflammatory itch
- PMID: 39056456
- PMCID: PMC11657048
- DOI: 10.1111/all.16260
Anaplastic lymphoma kinase as a new therapeutic target in inflammatory itch
Conflict of interest statement
NG is (or was) collaborating or consulting or member of scientific advisory board for Genoskin (CSO, shareholder), Escient Pharmaceuticals, Aikium, CEVA, MaxiVax, Boehringer Ingelheim, Novartis, Sanofi, ArgenX.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
